Sermion tablets, film-coated, 30 mg, No. 30 (15 x 2)

In stock: 1
$76.00

Composition

Active ingredient: nicergoline;

1 tablet contains 30 mg of nicergoline;

excipients: calcium hydrophosphate dihydrate, microcrystalline cellulose, magnesium stearate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, titanium dioxide (E 171), polyethylene glycol 6000, yellow iron oxide (E 172), silicone.

Dosage Form

Film-coated tablets.

Main physical and chemical properties: round, biconvex tablets coated with an opaque yellow film coating.

Pharmacotherapeutic group

Agents affecting the cardiovascular system. Peripheral vasodilators. Ergot alkaloids. Nicergoline. ATC code C04A E02.

Pharmacological properties

Pharmacodynamics.

Nicergoline is an ergoline derivative with alpha-1-adrenergic blocking activity when administered parenterally. After oral administration, nicergoline undergoes rapid and extensive metabolism, forming a number of metabolites that also exert activity at various levels of the central nervous system.

When administered orally, Sermion® exhibits numerous neuropharmacological effects: it not only increases glucose uptake and utilization in the brain and enhances the biosynthesis of proteins and nucleic acids, but also affects various neurotransmitter systems.

Sermion® improves cerebral cholinergic functions in aged animals. Long-term administration of nicergoline to aged rats prevented the age-related decrease in acetylcholine levels (in the cerebral cortex and striatum), and also led to a reduction in acetylcholine release (in the hippocampus) under in vivo conditions. Following long-term oral administration of Sermion®, an increase in cholinyl-acetyltransferase activity and muscarinic receptor density was also observed. Furthermore, in both in vitro and in vivo studies, nicergoline significantly reduced acetylcholinesterase activity. In these experimental studies, neurochemical effects were observed concurrently with sustained improvements in behavioral responses. For example, in a maze test, adult animals that had been administered Sermion® over a prolonged period exhibited responses similar to those seen in young animals.

Administration of Sermion® to animals also reduced the manifestations of cognitive impairment induced by various agents (hypoxia, electroconvulsive therapy (ECT), scopolamine). Oral administration of low doses of Sermion® increases dopamine metabolism in mature animals, particularly in the mesolimbic region, presumably by modulating dopaminergic receptors. Sermion® enhances signal transduction mechanisms in cells of adult animals. Both single-dose and chronic oral administration of the drug resulted in increased metabolism of basal and agonist-sensitive phosphoinositides. Sermion® also increases the activity and membrane translocation of calcium-dependent isoforms of protein kinase C. These enzymes are involved in the secretion of the soluble amyloid precursor protein, which leads to increased release of this precursor and a reduction in the production of pathological beta-amyloid, as demonstrated in human neuroblastoma cell cultures.

Thanks to its antioxidant effect and ability to activate detoxification enzymes, Sermion® prevents nerve cell death caused by oxidative stress and apoptosis. Sermion® mitigates the age-related decline in the expression of neuronal nitric oxide synthase mRNA, which may also contribute to improved cognitive function.

Pharmacodynamic studies in humans were conducted using computerized EEG techniques involving young and older volunteers, as well as elderly patients with cognitive disorders. Sermion® normalized EEG findings in elderly patients and younger adults under hypoxic conditions, increasing α- and β-activity and decreasing δ- and θ-activity. In patients with mild or moderate dementia of various etiologies (Alzheimer’s-type senile dementia and multi-infarct dementia), long-term use of Sermion® (for 2–6 months), positive changes in evoked potentials and responses to stimulation were observed; these changes correlate with an improvement in clinical symptoms. In light of the above, it is evident that nicergoline acts by modulating a broad spectrum of cellular and molecular mechanisms involved in the pathogenesis of dementia. More than 1,500 patients with dementia (Alzheimer’s-type, vascular, and mixed-type) who received nicergoline at a dose of 60 mg per day or a placebo. Following long-term treatment with nicergoline, a sustained reduction in the manifestations of cognitive and behavioral disturbances associated with dementia was observed. Improvement in patients’ condition became apparent after 2 months of treatment and was maintained throughout one year of treatment.

The drug has a positive effect on attention, concentration, and emotional state. It has a beneficial effect not only on cognitive function but also on mood and behavioral disturbances.

Pharmacokinetics.

Absorption. Following oral administration, nicergoline is rapidly and almost completely absorbed. The peak radioactivity level after healthy volunteers received low doses (4–5 mg) of H3-labeled nicergoline was observed after 1.5 hours. However, following oral administration of therapeutic doses (30 mg) of C14-labeled nicergoline to healthy volunteers, the peak serum radioactivity was observed 3 hours after dosing. Following oral administration of nicergoline (15 mg) to healthy volunteers, the area under the serum radioactivity curve was 81% and 6% of the value calculated for the two major metabolites of nicergoline — MDL and MMDL, respectively. Peak plasma concentrations of MDL were reached approximately 3–5 hours after a single or multiple doses of a 30-mg tablet. Peak plasma concentrations of MMDL were reached approximately 0.5–1 hour after a single 30-mg dose.

The absolute bioavailability of nicergoline after oral administration is approximately 5% due to first-pass metabolism. Based on the results of measuring levels of the major metabolite MDL, it was established that in healthy volunteers following oral administration of a 30–60 mg dose, the pharmacokinetics of nicergoline are linear. Following a single oral dose of 30 mg of nicergoline, no significant effect of food on the pharmacokinetics of MDL and MMDL was observed.

Distribution. The drug distributes rapidly and extensively into tissues, as reflected by the short distribution phase of serum radioactivity. The volume of distribution of nicergoline in the central compartment (approximated by dividing the dose by the plasma concentration of nicergoline at the first sampling time point following intravenous administration of a nominal dose of 2 mg) is relatively high (224 L), potentially reflecting the distribution of nicergoline into blood cells and/or tissues. Nicergoline binds with high affinity to human plasma proteins, with an affinity for α-acid glycoprotein that is four times higher than that for serum albumin. The percentage of binding remains relatively constant as the concentration of nicergoline increases from 1 μg/mL to 500 μg/mL. Both metabolites of nicergoline, MDL and MMDL, are characterized by low binding levels, approximately 14.7% and 34.7%, respectively, in the concentration range of 50–200 ng/mL.

Metabolism and Excretion. The drug is primarily excreted in the urine. Within 120 hours after administration, approximately 82% of the total amount of radioisotope-labeled nicergoline is excreted by the kidneys, and 10% is excreted in the feces. Nicergoline undergoes extensive metabolism, primarily through the hydrolysis of ether bonds to form MMDL, followed by demethylation to form MDL (via the catalytic action of the CYP2D6 isoenzyme). Therefore, the pharmacokinetics of nicergoline and its metabolites are affected in patients with a genetic deficiency of CYP2D6. The active metabolites formed (MMDL and MDL) are conjugated with glucuronic acid. The proportion of the major metabolite MDL accounts for 51% of the total dose and 76% of the radioactivity detected in urine following oral administration of a 15-mg dose. The mean terminal half-life of MDL ranges from approximately 11 to 20 hours.

Special Patient Populations. The effect of renal impairment on the pharmacokinetics of nicergoline was evaluated in patients with mild (creatinine clearance (Clcr) 60–80 mL/min), moderate (Clcr 30–50 mL/min), and severe (Clcr 10–25 mL/min) renal impairment. In patients with mild (n = 5), moderate (n = 5), and severe (n = 4) renal impairment, significant differences were observed in the amount of MDL which was excreted in the urine within 120 hours after oral administration of 30 mg of nicergoline (38.1%, 42.6%, and 25.7% of the administered dose, respectively); for MMDL, the corresponding values were 1.7%, 0.6%, and 0.2%. Patients with severe renal impairment showed a significant reduction in urinary MDL excretion compared with the other two groups. In addition, patients with mild, moderate, or severe renal impairment showed a mean reduction in urinary MDL excretion (0–72 hours) of 32%, 32%, and 59%, respectively, compared with patients with normal renal function who participated in another study using 30-mg tablets.

The pharmacokinetics of nicergoline in patients with hepatic impairment have not been studied.

The pharmacokinetics of nicergoline have not been studied in children.

The effect of age (in elderly patients) on the pharmacokinetics of nicergoline has not been fully studied.

Indications

Post-stroke conditions, vascular dementia (multi-infarct dementia), degenerative conditions associated with dementia (senile and presenile Alzheimer’s-type dementia, dementia associated with Parkinson’s disease).

Contraindications

Hypersensitivity to nicergoline, ergot alkaloids, or any other component of the drug. Recent myocardial infarction, acute bleeding, orthostatic hypotension, severe bradycardia.

Drug Interactions and Other Interactions

This medication should be used with caution in combination with:

antihypertensives: nicergoline may potentiate their effects. Nicergoline may potentiate the effects of beta-blockers on the heart;

sympathomimetics (alpha- and beta-): nicergoline may antagonize the vasoconstrictive effect of sympathomimetics by blocking alpha-adrenergic receptors (see the “Special Considerations for Use” section);

drugs metabolized by the CYP2D6 isoenzyme: since nicergoline is metabolized by the CYP2D6 isoenzyme, the possibility of interactions with other drugs metabolized by the same pathway cannot be ruled out;

antiplatelet agents and anticoagulants (e.g., acetylsalicylic acid): enhances the effect on hemostasis, which may result in prolonged bleeding time;

drugs that affect uric acid metabolism: nicergoline may lead to an asymptomatic increase in plasma uric acid concentrations.

Special Considerations for Use

Studies involving single or multiple doses of nicergoline have shown that nicergoline may lower systolic blood pressure and, to a much lesser extent, — diastolic blood pressure in patients with normal blood pressure and in patients with elevated blood pressure. These effects may vary, as other studies have not shown changes in systolic or diastolic blood pressure.

Patients taking nicergoline should use sympathomimetics (alpha- and beta-receptor agonists) with caution (see the section “Interactions with Other Medications and Other Types of Interactions”).

This medication should be used with caution in patients with hyperuricemia or a history of gout and/or during concomitant treatment with medications that may affect the metabolism and excretion of uric acid (see the “Adverse Reactions” section).

The development of fibrosis (e.g., pulmonary fibrosis, cardiac fibrosis, heart valves, and retroperitoneal fibrosis) has been associated with the use of certain ergot alkaloids, which exhibit agonist activity at serotonin 5-HT2β receptors.

Symptoms of ergotism (including nausea, vomiting, diarrhea, abdominal pain, and peripheral vasoconstriction) have been reported with the use of certain ergot alkaloids and their derivatives.

Before prescribing this class of medications, physicians should familiarize themselves with the signs of ergot overdose.

The drug Sermion®, 30 mg tablets, contains less than 1 mmol of sodium (23 mg) per tablet. Patients on a low-sodium diet may be informed that this medication is virtually sodium-free.

Use during pregnancy or breastfeeding.

Pregnancy

Nicergoline has no toxic effect on the reproductive function of pregnant female rats and rabbits. No clinical studies have been conducted in pregnant women. Given the approved indications, the use of nicergoline by pregnant or breastfeeding women is unlikely. During pregnancy, nicergoline should be used only when the potential benefit to the patient outweighs the potential risks to the fetus.

Breastfeeding

It is unknown whether nicergoline is excreted in breast milk; therefore, Sermion® should not be used by breastfeeding women.

Fertility

In a study in rats, nicergoline had no effect on fertility.

Effect on reaction time when operating motor vehicles or other machinery.

Although the clinical effects of Sermion® are used to improve attention and concentration, its effect on the ability to drive or operate machinery has never been studied. Therefore, treatment should be administered with caution, taking into account the patient’s underlying condition. When driving or operating machinery, patients should be aware that dizziness or drowsiness may occur from time to time (see the “Adverse Reactions” section).

Dosage and Administration

The recommended daily dose is 1 tablet 1 or 2 times daily (30–60 mg). The usual daily dose for adults is 30 mg. It may be temporarily increased to 60 mg.

Based on the results of pharmacokinetic and tolerability studies, no dose adjustment is necessary for elderly patients.

Patients with impaired renal function.

Since renal excretion is the primary route of elimination (80%) for nicergoline and its metabolites, it is a dose reduction is recommended (see the “Pharmacokinetics” section). The therapeutic effect develops gradually. Since therapy is typically administered over a long period, the physician should evaluate the appropriateness of continuing treatment at least every 6 months.

Children. The safety and efficacy of nicergoline in children have not been established. No data are available.

Overdose

When high doses of nicergoline are used, a temporary decrease in blood pressure may occur. This condition usually does not require special treatment; resting for a few minutes is sufficient. In exceptional cases of severe cerebral and cardiac circulatory insufficiency, the use of sympathomimetics and continuous monitoring of blood pressure are recommended.

Side Effects

Frequency categories are expressed as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); frequency unknown (frequency cannot be estimated from the available data).

Within each frequency group, adverse reactions are listed in order of decreasing severity.

Psychiatric disorders. Uncommon: anxiety, confusion, insomnia.

Nervous system disorders. Uncommon: drowsiness, dizziness, headache; frequency unknown: sensation of heat*.

Vascular disorders. Uncommon: hypotension, flushing.

Gastrointestinal disorders. Common: abdominal discomfort; uncommon: diarrhea, nausea, constipation.

Skin and subcutaneous tissue disorders. Uncommon: itching; frequency unknown: rash*.

General disorders and administration site conditions. Frequency unknown: fibrosis*.

Laboratory findings. Uncommon: increased blood uric acid levels.

*The frequency of adverse reactions was assessed based on studies in the Comprehensive Safety Summary (reactions that occurred after the start of treatment for any reason). This pooled safety analysis includes data from eight (8) double-blind controlled studies involving patients with mild or moderate dementia, of whom 1,246 patients received nicergoline. The “rule of three” was not applied because the nicerogoline Comprehensive Safety Summary database contained fewer than 3,000 patients.

Reporting of Suspected Adverse Reactions.

Reporting suspected adverse reactions during the postmarketing period is an important measure. This allows for continued monitoring of the benefit-risk profile of the drug. Physicians are encouraged to report any suspected adverse reactions.

Shelf life

3 years.

Storage conditions

Store at a temperature not exceeding 25 °C.

Packaging

15 tablets per blister pack; 2 blister packs per cardboard box.

Manufacturer

Pfizer Italia S.r.l.

Address

Località Marino del Tronto – 63100 Ascoli Piceno (AP), Italy.